Table 1. Clinical Characteristics of the Study Population for Circulating MiRNAs Profiling.
| Control cases (n = 13) | UA patients (n = 13) | P value | |
| Baseline data | |||
| Sex, M/F | 5/8 | 7/6 | 0.431 |
| Age (yrs) | 56±9 | 61±8 | 0.159 |
| SBP (mm Hg) | 125±12 | 133±13 | 0.139 |
| DBP (mm Hg) | 76±6 | 80±11 | 0.281 |
| BMI (kg/m2) | 26±5 | 25±4 | 0.762 |
| LVEF (%) | 69±6 | 68±6 | 0.624 |
| HR (bpm) | 70±9 | 70±10 | 0.935 |
| hs-CRP (mg/dl) | 1.18 | 1.25 | 0.951 |
| PLT (×1012/L) | 225±72 | 209±43 | 0. 510 |
| Glucose (mmol/l) | 5.02±0.83 | 4.95±0.51 | 0.806 |
| Lipid profile | |||
| LDL cholesterol (mmol/l) | 2.31±0.86 | 2.42±0.56 | 0.718 |
| HDL cholesterol (mmol/l) | 1.02±0.23 | 0.97±0.30 | 0.630 |
| TC (mmol/l) | 3.96±1.02 | 3.96±0.60 | 0.996 |
| Risk factors | |||
| Cigarette smoking, % | 7.7 | 23.1 | 0.593 |
| Hypertension, % | 53.8 | 84.6 | 0.202 |
| Diabetes mellitus, % | 15.4 | 30.8 | 0.645 |
| Hyperlipemia, % | 53.8 | 61.5 | 0.691 |
| Drug Administration | |||
| Statin, % | 53.8 | 61.5 | 0.691 |
| CCB, % | 30.8 | 38.5 | >0.99 |
| Beta-blocker, % | 38.5 | 69.2 | 0.116 |
| Aspirin, % | 38.5 | 61.5 | 0.239 |
| Clopidogrel, % | 30.8 | 46.2 | 0.420 |
| ACEI, % | 15.4 | 23.1 | >0.99 |
| ARB, % | 15.4 | 15.4 | >0.99 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; HR, heart rate; PLT, platelet; CRP, C-reactive protein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker. All P values represent comparisons between UA patients and controls. Comparisons between groups were performed with Student's t test or Mann–Whitney U test for continuous variables and with the Fischer exact test or χ2 test for categorical variables.